Mallinckrodt plc MNK announced that the FDA has cleared its Inomax DS plus MRI device for the delivery of Inomax for inhalation during MRI procedures. The system will deliver Inomax for inhalation ...

-- INOMAX® DS and INOMAX® DSIR Now Compatible with Nearly 60 Respiratory Care Devices -- Hampton, NJ, March 21, 2012 – Ikaria, Inc., a critical care company focused on developing and commercializing ...

Mallinckrodt plc (NYSE: MNK), a leading specialty biopharmaceutical company, today announced that INOmax ® (nitric oxide) for inhalation has received regulatory approval in Australia and Japan for ...

-- /PRNewswire/ -- Ikaria, Inc. announced today that it has completed a remediation action for its INOMAX® DS drug-delivery systems related to a fretting corrosion. This class I recall notice is being ...

October 14, 2009 — The US Food and Drug Administration (FDA) has approved safety labeling revisions to warn of the risk for leukopenia/neutropenia in patients receiving antipsychotics, including ...

April 30 (Reuters) - Mallinckrodt Plc said on Thursday it would fund a trial conducted by medical experts, evaluating the potential benefits of its respiratory therapy, INOmax, as a treatment for lung ...

Affected serial numbers include DS20070005-DS20100865. This product was manufactured from March 12, 2007 through February 2, 2011 and distributed from September 4, 2007 through February 2, 2011.

Mallinckrodt plc is engaging with the U.S. FDA, NIH and the Biomedical Advanced Research and Development Authority to address the potential use of its INOmax (nitric oxide) inhaled gas to treat ...

Mallinckrodt plcMNK announced that the FDA has cleared its Inomax DS plus MRI device for the delivery of Inomax for inhalation during MRI procedures. The system will deliver Inomax for inhalation into ...